NewLimit
Backed by
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
Senior Scientist, mRNA engineering
Scientist/Senior Scientist, PK/PD Assays
Computational Biologist
VP, Clinical Development
Senior Research Associate, PK/PD Assays
Data Scientist
Director, Operations
Senior/Research Associate
Scientist/Senior Scientist, Immunology
Scientist/Senior Scientist
Senior Research Associate, Metabolism
Senior/Research Associate, Drug Product Development
Explore similar companies to NewLimit
Industries
Investors
Cities